The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q2 2023 call → NOWe need to determine if management conveys that the reported results do not represent the business as it is actually running today — that the business has moved ahead of the reported period. Look for management's own words indicating a gap between the reported numbers and current operations, grounded in concrete things already in place. Key points from the call: - Strong first half results, reiterating full-year guidance. - KEDRAB sales increased significantly, with extension of distribution agreement through 2026. - FDA approval for manufacturing CYTOGAM at Israeli facility, and Health Canada approval recently obtained. Expect to initiate sales from Israeli facility in Q4. - Kamada Plasma expansion, second center opening early 2024. - InnovAATe trial enrollment ramping, 62 patients enrolled (~30%). - Positive EMA scientific advice confirming study design. - $60 million financing expected to close later this quarter, providing financial flexibility for BD. Does management indicate that the reported period is stale relative to the operating present? They mention that the second half will have enhanced profitability, and that they expect continued growth. But is there a sense that the business has already moved to a different level? They talk about recent approvals (Health Canada) and expected sales from Israeli facility in Q4, but that's future. They mention the financing closing later this quarter, but that's not yet closed. They talk about enrollment ramping, but that's ongoing. The question is whether management conveys that the reported results do not represent the current business. They do say that the first half momentum will extend, and that they expect enhanced profitability in the second half. But that's typical guidance. They also mention that the second quarter of 2022 was affected by a labor strike, but that's about prior year. The key is whether management draws attention to a gap between the reported period and what is now happening. They mention the CYTOGAM tech transfer approvals, but that's about future sales. They mention the financing, but that's not yet closed. They mention the InnovAATe trial progress, but that's a development program. I don't see management explicitly saying that the reported numbers are behind the current business. They are just reporting results and giving guidance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.